Invenra's Commercial Pivot: New CCO to Drive Antibody Platform Growth

MADISON, WI – May 20, 2026 – In a move signaling a decisive pivot from scientific discovery to global commercial strategy, Madison-based Invenra, Inc. has appointed Nancy J. Sandy as its first Chief Commercial Officer. The strategic hire aims to capitalize on the momentum of its pioneering multispecific antibody platforms and convert years of advanced research into market leadership.

For years, Invenra has been a quiet force in biotechnology, developing a sophisticated technology toolbox for creating complex antibody therapeutics. The company has gained recognition for its B-Body® bispecific and the newly launched T-Body™ trispecific antibody platforms. Now, with a key partnership asset in clinical trials and a growing roster of global collaborators, Invenra is stepping into the commercial spotlight, and Sandy is tasked with directing the beam.

A New Era of Commercial Leadership

The appointment of Nancy J. Sandy is a clear statement of intent. She is not merely a sales leader but a seasoned executive with a formidable track record of transforming scientific innovation into commercial success. Most recently, Sandy served as CEO of Taconic Biosciences, a major global provider of research models. During her nine-year tenure, she guided the company through two successful exits, delivering a 3X return on initial investment and cementing her reputation as a leader who can pair scientific vision with rigorous business execution.

Her experience spans life science tools, laboratory equipment, and medical devices, giving her a panoramic view of the industry Invenra aims to serve. This background is precisely what the company needs as it seeks to scale its opportunities with dedicated commercial leadership for the first time.

"Invenra offers a differentiated, proprietary discovery engine and platform portfolio that researchers around the world need to tackle the hardest targets in oncology and immunology," said Roland Green, Founder and CEO of Invenra. "Nancy's appointment gives us the commercial leadership to match our scientific ambition and accelerate how quickly we can bring these innovations to partners working to develop the next generation of therapeutics."

Sandy herself highlighted the disruptive potential of the company's technology. "Multispecific antibodies are one of the most exciting frontiers in drug development, and Invenra is empowering researchers to make better antibodies using a radically simplified, next generation platform," she stated. "I’m focused on ensuring the world's leading scientists know there is a proven alternative to time-consuming, legacy techniques."

The Science Driving the Strategy

At the heart of Invenra's commercial ambitions lies its proprietary technology. The company's platforms are designed to overcome the significant challenges associated with developing multispecific antibodies—therapeutics that can bind to two or more targets simultaneously, offering new ways to fight complex diseases like cancer.

The B-Body® bispecific platform is engineered for speed and quality, capable of delivering optimized antibody candidates in as little as four months. Its key advantage is a focus on developability—ensuring the resulting antibodies are stable, easy to manufacture, and suitable for patient-friendly subcutaneous delivery. This feature directly addresses a major bottleneck in biopharmaceutical production.

Launched in 2025, the T-Body™ trispecific platform represents the next frontier. These highly complex molecules can engage three different targets, enabling novel therapeutic mechanisms such as enhancing immune cell activation or increasing specificity to tumor cells. Invenra's T-Body™ platform boasts robust expression yields and a streamlined one-step purification process, making the development of these advanced constructs feasible and scalable for partners.

This focus on manufacturability and efficiency positions Invenra to compete effectively in a crowded market that includes giants like Regeneron and Amgen. By offering a faster, more reliable path to complex therapeutics, the company provides a compelling value proposition to pharmaceutical and biotech partners of all sizes.

From Lab to Clinic: Building Momentum

The theoretical advantages of Invenra's platforms are being validated by tangible clinical progress. A critical milestone was achieved through its collaboration with Exelixis, Inc., which advanced a bispecific antibody discovered using Invenra's technology into a Phase 1 clinical trial in May 2025.

The drug candidate, XB628, is a first-in-class natural killer (NK) cell engager that simultaneously targets two key immune pathways, NKG2A and PD-L1. It is being tested in patients with recurrent or metastatic solid tumors. The advancement followed promising preclinical data presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. This is not the first success for the partnership; an earlier collaboration led to XB010, an antibody-drug conjugate (ADC) that entered Phase 1 trials in 2024. These clinical milestones provide crucial validation that Invenra's discovery engine can produce viable drug candidates, a key selling point for Sandy's new commercial team.

Forging a Global Partnership Network

Invenra's recent string of high-profile partnerships underscores the growing industry demand for its technology. These collaborations form the foundation of the commercial strategy that Sandy will now amplify.

In January 2025, Invenra partnered with Finnish pharmaceutical company Orion to discover bispecific antibodies for oncology and pain, combining Invenra's discovery prowess with Orion's development and commercialization expertise.

Later that year, in October 2025, a strategic collaboration was formed with Xcellon Biologics, a specialist in ADCs. This partnership leverages both the B-Body® and T-Body™ platforms to create next-generation bispecific and trispecific ADCs, demonstrating the versatility of Invenra's technology in one of biotech's hottest fields.

Perhaps the most significant validation came in February 2026, when Invenra signed a co-exclusive licensing agreement for its B-Body® platform with Twist Bioscience. The deal involved a substantial financial commitment from Twist, including a $5 million upfront cash payment, $15 million in stock, and the acquisition of a 6% ownership stake in Invenra. This arrangement not only provides a major capital infusion but also dramatically expands the reach of the B-Body® platform by leveraging Twist's extensive commercial infrastructure.

With a validated technology, a pipeline delivering clinical candidates, and a robust network of strategic partnerships, Invenra has methodically assembled all the components for success. The appointment of Nancy J. Sandy is the final, critical piece of the puzzle—a catalyst intended to ignite these components into a sustained engine of commercial growth and establish Invenra as an indispensable partner in the future of drug discovery.